Deismireacht APA

Fonseca, V. A., Alvarado-Ruiz, R., Raccah, D., Boka, G., Miossec, P., & Gerich, J. E. (2012). Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). American Diabetes Association.

Citação norma Chicago

Fonseca, Vivian A., Ricardo Alvarado-Ruiz, Denis Raccah, Gabor Boka, Patrick Miossec, and John E. Gerich. Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A Randomized, Double-blind, Placebo-controlled Trial in Patients With Type 2 Diabetes (GetGoal-Mono). American Diabetes Association, 2012.

Deismireacht MLA

Fonseca, Vivian A., et al. Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A Randomized, Double-blind, Placebo-controlled Trial in Patients With Type 2 Diabetes (GetGoal-Mono). American Diabetes Association, 2012.

Rabhadh: D'fhéadfadh nach mbeadh na deismireachtaí seo 100% cruinn i gcónaí.